Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 56

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 56
---
 of directors was aware of these interests and considered them, among other matters, in approving the Divestiture Agreement. Additional information on these interests
can be found in the section entitled “The Divestiture—Interests of Aadi’s Directors and Executive Officers in the Divestiture” beginning on page 71 of this proxy statement.

Lawsuits may be filed against Aadi challenging the Divestiture and an adverse ruling in any such lawsuit may prevent the Divestiture from being completed at all or from being completed within the expected time frame.

One of the conditions to the completion of the Divestiture is the absence
of any judgment or law issued or enacted by any governmental entity of competent jurisdiction, in each case that has been entered or enacted that prevents or materially impairs the consummation of the Divestiture. Accordingly, if litigation is or
enacted filed challenging the Divestiture and a plaintiff is successful in obtaining an order enjoining completion of the Divestiture, then such order may prevent the Divestiture from being completed at all or from being completed within the
expected time frame.

Risks Related to the PIPE Financing

Our stockholders will experience significant dilution as a result of the PIPE Financing if the PIPE Financing Proposal is approved at the Special Meeting. The number of shares we have agreed to sell in the PIPE Financing is significant in relation to the number of outstanding shares of our common stock.

Our stockholders will experience significant dilution as a result of the PIPE Financing if the PIPE Financing Proposal is approved at the Special Meeting.
Pursuant to the Subscription Agreement and the terms of the PIPE Financing, we have agreed to issue and sell to the PIPE Investors (i) 21,592,000 shares of our common stock and (ii) 20,076,500 Pre-Funded Warrants to acquire common stock, subject to
stockholder approval at the Special Meeting. If the PIPE Financing Proposal is approved and the PIPE Offering is completed, we will have 46,272,708 outstanding shares of common stock and an additional 20,076,500 Pre-Funded Warrants outstanding.

- 38 -

After the closing of the PIPE Financing, the shares of common stock issued to the PIPE Investors will account for approximately 47% of the total shares outstanding (based on 24,696,568 total
shares outstanding as of January 30, 2025 and after giving effect to the 21,592,000 shares expected to be issued in the PIPE Financing). If the PIPE